dBET1 is a potent BRD4 protein degrader based on PROTAC technology with an EC50 of 430 nM.

tri-GalNAc biotin is a biotinylated ASGPR (Asialoglycoprotein receptor) ligand. tri-GalNAc biotin promotes cellular uptake of neutravidin (NA) via ASGPR. tri-GalNAc biotin delivers neutravidin to lysosomes for degradation. tri-GalNAc biotin can be used for research of LYsosome TArgeting Chimera (LYTAC).

Tri-GalNAc-biotin is an asialoglycoprotein receptor (ASGPR) ligand for lysosomal targeting chimera (LYTAC) research and development, comprising a triantennary N-acetylgalactosamine (GalNAc) joined by a PEG linker to DBCO.

Triantennary GalNAc Acid is an asialoglycoprotein receptor (ASGPR) ligand for lysosomal targeting chimera (LYTAC) research and development.

tri-GalNAc-PEG3-Azide is a functionalized asialoglycoprotein receptor (ASGPR) ligand for lysosomal targeting chimera (LYTAC) research and development; each molecule incorporates three ASGPR ligands with a PEG3 linker and azide group reactive handle ready for conjugation. Upon binding to the ASGPR, tri-GalNAc conjugates are efficiently internalized via ASGPR-mediated endocytosis. tri-GalNAc conjugation can be employed as a strategy to effectively deliver cargo such as RNA or Cas9 complexes in a cell-specific manner to hepatocytes. Can be used to generate LYTACs, or labeled with dye for tissue imaging.

KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases.

CFT8634 is an oral activity degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors.

NX-5948,be also known as BTK-IN-24,is an oral BTK degrader.

SelDeg51 (Selective Degrader of FKBP51) is a potent, selective FKBP51 PROTAC with Kd of 18 nM, Emax=90%.

ARV-102 is a highly potent, orally bioavailable PROTAC that targets LRRK2 with a of 0.14 nM, designed to cross the blood-brain barrier to address neurodegenerative diseases. By hijacking the body’s ubiquitin-proteasome system, it achieves deep and sustained degradation of LRRK2 protein in both peripheral tissues and the central nervous system, offering a potentially superior therapeutic approach over traditional kinase inhibitors.

C199 is a PROTAC degrader targeting PRMT4 (DC50 = 106 nM). C199 shows high selectivity for PRMT4 over other protein arginile methyltransferases. C199 exhibits strong cell degradation ability. C199 induces apoptosis in MM cell lines. C199 efficiently clears PRMT4 protein via the VHL-proteasome pathway. C199 has a relatively long half-life and shows strong anti-multiple myeloma (MM) tumor activity.

Tri-GaNAc-PEG8-NH2-CH2CH2-NH2-bromoacetyl is a compound that targets the asialoglycoprotein receptor (ASGPR) and is utilized to conjutate with antibody.

Tri-GaNAc-PEG8-Gly-Gly-Gly is a compound that targets the asialoglycoprotein receptor (ASGPR) and is utilized to conjutate with antibody.

Triantennary GalNAc ligand is known to bind Asialo Glycoprotein Receptor (ASGPR). The ligand is functionalized with dibenzocyclooctyne for click chemistry.

Triantennary GalNAc ligand is known to bind Asialo Glycoprotein Receptor (ASGPR). The ligand is functionalized with dibenzocyclooctyne for click chemistry

(β-D-GalNAc-sp)3-NHC(O)-(CH2)2-NHC(O)-PEG3-(CH2)2-N3 Tris-β-D-GalNAc ligands bind with asialoglycoprotein receptors (ASGPR) that are highly expressed on hepatocytes resulting in rapid endocytosis of the ligand along with conjugated payloads

An amine-reactive asialo glycoprotein receptor (ASGPR) ligand.

A thiol-reactive asialo glycoprotein receptor (ASGPR) ligand.

GSK 525762A is a potent small molecule inhibitors that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4).

ASGPR ligand-1 is a compound that targets the asialoglycoprotein receptor (ASGPR) and is utilized in various disease research contexts .

The trivalent β-GalNAc ligand is specific for Asialo Glycoprotein Receptors (ASGPR) on hepatocyte cells. β-Ala-PEG3 acts as linker/spacer between triantennary GalNAc and Fluorescein isothiocyanate (FITC).

Tris-GalNAc-GABA-NH2 linked via PEG2k to phospholipid (DSPE or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine) where GABA = gamma-Aminobutyric acid, or γ-aminobutyric acid.

Trivalent β-GalNAc Ligand with discrete, monodisperse, azido-functionalized PEG3 linker/spacer

Tris-GalNAc ligands bind to Ashwell-Morell (also Asialoglycoprotein receptor or ASGPR) receptors and are validated ligands in medicinal chemistry for liver-specific drug delivery.

The trivalent β-GalNAc Ligand is specific for Asialo Glycoprotein Receptors on hepatocyte cells. β-Alanine-PEG3 acts as linker/spacer between multivalent GalNAc and biotin.

Tri-GalNAc-NHS ester is a LYsosome TArgeting Chimera (LYTAC) and a ligand of asialoglycoprotein receptor (ASGPR). ASGPR is a lysosomal targeting receptor specifically expressed on liver cells, for the degradation of extracellular proteins including membrane proteins. Tri-GalNAc-NHS ester can be used as a protein degrader and it can be used for the research of LYTAC.

PT-179 is a novel orthogonal immunomodulatory drug (IMiD) derivative that selectively binds to CRBN without inducing degradation of off-target proteins. It demonstrates potent activity in degrading proteins fused to SD40, regardless of whether the fusion occurs at the N or C terminus.

BSJ-05-037 is a potent and selective heterobifunctional degrader of ITK with DC50 of 17.6-41.8 nM in TCL lines DERL-2 and Hut78. BSJ-05-037 induces potent degradation of ITK dependent on CRBN, neddylation, and the proteasome. BSJ-05-037 induces GATA-3 loss and decreases chemotherapy resistance in vitro. BSJ-05-037 disrupts TCR signaling, downregulates the Th2-associated transcription factor GATA-3, and can overcome chemotherapy resistance in TCL models in vivo.